AIM ImmunoTech News - September 3, 2026
AIM ImmunoTech Locks Down 15-Year European Patent for Long COVID Drug — But Can a $7 Million Company Turn Paper Protection Into Real Revenue?
Shares of AIM ImmunoTech jumped 10.8% to $0.26 after the micro-cap biotech announced it secured patent protection across Europe and the United Kingdom for its...
🟢 AIM ImmunoTech is trading 10.78% up today after European and UK patent protection through 2041
AIM ImmunoTech is trading 10.78% up now at $0.26 after securing European and United Kingdom patent protection for Ampligen’s Long COVID use through June...
🟢 AIM ImmunoTech is trading 8.35% up today after European Ampligen patent protection through 2041
AIM ImmunoTech is trading at $0.25 (+8.35%) after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment through June...
🟢 AIM ImmunoTech is trading 7.29% up in pre-market after European Long COVID patent protection through 2041
AIM ImmunoTech is trading 7.29% up at $0.25 in pre-market after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment...